Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
Verona Pharma will host an investment community webcast and conference call at 8:30 a.m. EDT / 1:30 p.m. BST on Tuesday, August 9, 2022, to discuss the ENHANCE-2 results, its second quarter financial results and the corporate update.
To participate, please dial one of the following numbers and reference conference ID 2165062:
+1-888-317-6003 for callers in the United States
+1-412-317-6061 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days. An electronic copy of the second quarter 2022 results press release will also be made available today on the Company’s website.
For further information please contact:
Verona Pharma plc | US Tel: +1-833-417-0262 |
Victoria Stewart, Director of Investor Relations and Communications | |
|
|
Argot Partners | Tel: +1-212-600-1902 |
Kimberly Minarovich / Michael Barron |
|
|
|
Optimum Strategic Communications | Tel: +44 (0)203 882 9621 |
Mary Clark / Rebecca Noonan / Zoe Bolt |
|
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.